WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Tourism boosts China's social, economic development
Katie Holmes cuts a casual figure in a t
Lewis Hamilton will begin his Ferrari career at the Australian Grand Prix next year
In Pictures: Rare celestial event totally eclipsed by thick cloud in Hong Kong
Forensic psychiatrist reveals the different types of stalkers
PLAYER RATINGS: Scores revealed for DIRE Liverpool stars who flopped in first leg against Atalanta
Man United legend Andy Cole accuses Mikel Arteta of 'mugging off' out
Cleanup of homeless encampment along Santa Ana River hits a snag in Newport Beach
Children are evacuated from school 'during an exam' after threat made via email
Controversial Antonio Brown pays tribute to 'legend' OJ Simpson after his death from cancer aged 76
French sports minister calls for sanctions after Monaco player tapes over anti
Revealed: The startling number of English